Regeneron Pharmaceuticals, Inc.

The forensic screens on file point in different directions, and none of them replaces reading the filings. The Beneish M-Score is -2.481, below the -1.78 threshold and labeled not in the elevated manipulation-risk zone. That means the screen did not flag a manipulation pattern, though a screen cannot prove the absence of one. The Altman Z″-Score of 9.21 sits in the safe zone, which is 2.60 or above, consistent with a balance sheet where equity of $31.26 billion makes up most of $40.56 billion in assets. The Piotroski F-Score reads 5 of 8 computable signals, a middling result that means only some of the computable checks were passed. Operating cash flow of $4.98 billion against net income of $4.5 billion gives a ratio of 1.11, so reported profit was backed by cash in 2025. The weaker points are the 1.0% revenue growth, the operating income decline, and the pace of repurchases. Remaining authorization fell from $1,322.2 million at January 31, 2026 to $688.2 million at March 31, 2026, before the April authorization of $3.0 billion. Four insiders, including two directors and the Executive Vice President of Commercial, adopted Rule 10b5-1 trading plans scheduled to end between November 2026 and May 2027. Readers may want to look at Note 16 for the patent litigation the filings reference, since the excerpts on file do not describe it.

Catalyst.Regeneron's 2025 revenue rose 1.0% to $14.34 billion from $14.2 billion in 2024, and net income reached $4.5 billion. Item 1 of the 10-K ties the business to a broad product line: EYLEA HD and EYLEA for eye diseases, Dupixent across several allergic and inflammatory indications, Libtayo for cancers, and Praluent for cholesterol. The MD&A excerpt on file for the quarter ended March 31, 2026 contains no revenue or segment discussion, so the drivers behind the 2025 result are not shown here. What the excerpt does show is capital return: the company repurchased about 1.05 million shares in the first quarter of 2026 and, in April 2026, authorized up to an additional $3.0 billion of repurchases.

Hidden risk.Operating income fell from $3.99 billion in 2024 to $3.58 billion in 2025, a decline of about 10%, while net income rose to $4.5 billion from $4.41 billion. Net income exceeded operating income by roughly $0.92 billion, so a meaningful part of 2025 profit came from items below the operating line. The data on file does not break those items out. The forward-looking statements in the 10-K also name biosimilar competition, drug pricing regulation, Medicare and Medicaid reimbursement, and possible termination of the Sanofi and Bayer agreements as risks. Liabilities rose to $9.3 billion from $8.41 billion over the same year, while long-term debt was $1.99 billion.